ABEONA THERAPEUTICS INC.
Moat Score — Abeona Therapeutics Inc.
Total Moat Score
18 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | ZEVASKYN is the first and only approved autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa, protected by FDA approval, an expanding intellectual property portfolio across vector engineering and manufacturing processes, and proprietary AIM capsid technology underlying the ophthalmic pipeline. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | In-house cGMP retroviral vector manufacturing at the Elisa Linton Center, using serum-free suspension bioreactor technology, gives Abeona real control over a notoriously difficult and expensive manufacturing process versus relying on third-party CDMOs, though the company is still far from being a low-cost producer given its ongoing losses. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As the sole approved therapy for a severe, previously untreatable ultra-rare disease, Abeona commands strong list pricing on ZEVASKYN and has already secured broad commercial and government payer coverage, though the addressable patient population is inherently small. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in gene therapy treatment; ZEVASKYN's clinical value to one RDEB patient is unrelated to how many other patients are treated. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | ZEVASKYN is a one-time, surgically administered autologous gene therapy rather than a chronic medication, meaning there is effectively no ongoing 'switching' decision for a treated patient, and the qualified treatment center model creates institutional stickiness once a hospital is onboarded and trained. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The combination of an ultra-rare addressable population and the extreme manufacturing complexity of autologous gene therapy limits how many companies can profitably operate in this exact niche, giving Abeona a defensible, if narrow, efficient-scale position as the first mover. |